AR061272A1 - Antagonistas de cgrp - Google Patents

Antagonistas de cgrp

Info

Publication number
AR061272A1
AR061272A1 ARP070102481A ARP070102481A AR061272A1 AR 061272 A1 AR061272 A1 AR 061272A1 AR P070102481 A ARP070102481 A AR P070102481A AR P070102481 A ARP070102481 A AR P070102481A AR 061272 A1 AR061272 A1 AR 061272A1
Authority
AR
Argentina
Prior art keywords
visceral pain
cgrp antagonist
cgrp antagonists
treat visceral
disorders
Prior art date
Application number
ARP070102481A
Other languages
English (en)
Inventor
Klaus Rudolf
Gerhard Schaenzle
Henri Doods
Kirsten Amdt
Thierry Bouyssou
Stephan Georg Mueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061272(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR061272A1 publication Critical patent/AR061272A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Método para prevenir y tratar el dolor visceral y los trastornos gastrointestinales tales como trastornos funcionales del intestino y enfermedades inflamatorias del intestino mediante el uso de cantidades eficaces de un compuesto que actua como antagonista de CGRP. Reivindicacion 1: El uso de un antagonista de CGRP (A) seleccionado de entre los compuestos de formulas (1) a (28), los enantiomeros, los diastereomeros, sus mezclas y sus sales fisiologicamente aceptables para la preparacion de un medicamento util para prevenir o tratar el dolor visceral.
ARP070102481A 2006-06-08 2007-06-08 Antagonistas de cgrp AR061272A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06011787 2006-06-08

Publications (1)

Publication Number Publication Date
AR061272A1 true AR061272A1 (es) 2008-08-13

Family

ID=37101671

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070102480A AR061271A1 (es) 2006-06-08 2007-06-08 Antagonistas de cgrp
ARP070102481A AR061272A1 (es) 2006-06-08 2007-06-08 Antagonistas de cgrp

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070102480A AR061271A1 (es) 2006-06-08 2007-06-08 Antagonistas de cgrp

Country Status (19)

Country Link
US (2) US20080139591A1 (es)
EP (2) EP2029233A2 (es)
JP (2) JP2009539800A (es)
KR (1) KR20090021214A (es)
CN (1) CN101500653A (es)
AR (2) AR061271A1 (es)
AU (1) AU2007255395A1 (es)
BR (1) BRPI0712492A2 (es)
CA (2) CA2654048A1 (es)
CL (2) CL2007001663A1 (es)
EA (1) EA200802381A1 (es)
EC (1) ECSP089025A (es)
IL (1) IL195712A0 (es)
MX (1) MX2008015562A (es)
NO (1) NO20085051L (es)
PE (2) PE20080370A1 (es)
TW (2) TW200808791A (es)
UY (2) UY30398A1 (es)
WO (2) WO2007141285A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0712492A2 (pt) * 2006-06-08 2012-08-21 Boehringer Ingelheim Int uso de antagonistas de cgpr e composição farmacêutica compreendendo antagonistas de cgpr.
WO2010070023A2 (en) * 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Formulations
FR2963738B1 (fr) * 2010-08-10 2012-09-28 Assist Publ Hopitaux De Paris Compose destine au traitement des douleurs abdominales fonctionnelles
HUE055505T2 (hu) 2011-05-20 2021-11-29 H Lundbeck As Anti-CGRP készítmények és alkalmazásuk
DK2709663T3 (da) 2011-05-20 2019-05-20 Alderbio Holdings Llc Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
AU2012258976B8 (en) 2011-05-20 2017-07-20 H. Lundbeck A/S Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
TWI636041B (zh) * 2015-08-12 2018-09-21 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
MX2021008267A (es) 2019-01-08 2021-08-05 H Lundbeck As Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5291960A (en) * 1992-11-30 1994-03-08 Ford Motor Company Hybrid electric vehicle regenerative braking energy recovery system
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20080070239A1 (en) * 2003-10-29 2008-03-20 University Of Rochester Detection of neureopeptides associated with pelvic pain disorders and uses thereof
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
CN101146799A (zh) * 2005-03-23 2008-03-19 贝林格尔·英格海姆国际有限公司 Cgrp拮抗剂、其制备方法以及其作为药物的用途
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (de) 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770087A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
BRPI0712492A2 (pt) * 2006-06-08 2012-08-21 Boehringer Ingelheim Int uso de antagonistas de cgpr e composição farmacêutica compreendendo antagonistas de cgpr.

Also Published As

Publication number Publication date
NO20085051L (no) 2008-12-19
US20080139537A1 (en) 2008-06-12
BRPI0712492A2 (pt) 2012-08-21
IL195712A0 (en) 2009-09-01
WO2007141285A1 (en) 2007-12-13
UY30398A1 (es) 2008-01-31
KR20090021214A (ko) 2009-02-27
EA200802381A1 (ru) 2009-06-30
PE20080370A1 (es) 2008-06-13
JP2009539799A (ja) 2009-11-19
CL2007001663A1 (es) 2008-01-25
AR061271A1 (es) 2008-08-13
US20080139591A1 (en) 2008-06-12
US7807666B2 (en) 2010-10-05
EP2029234A1 (en) 2009-03-04
ECSP089025A (es) 2009-01-30
PE20080153A1 (es) 2008-04-14
TW200815010A (en) 2008-04-01
TW200808791A (en) 2008-02-16
CA2654048A1 (en) 2007-12-13
CA2654047A1 (en) 2007-12-13
WO2007141284A3 (en) 2008-03-06
WO2007141284A2 (en) 2007-12-13
MX2008015562A (es) 2008-12-17
EP2029233A2 (en) 2009-03-04
CL2007001662A1 (es) 2008-01-25
UY30399A1 (es) 2008-01-31
AU2007255395A1 (en) 2007-12-13
CN101500653A (zh) 2009-08-05
JP2009539800A (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
AR061272A1 (es) Antagonistas de cgrp
AR047992A1 (es) Diaminopirimidinas como antagonistas de p2x3 y p2x2/3
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
ECSP077358A (es) Antagonistas del receptor 2 de citocina quimioatrayente de dipiperidina sustituida
CL2009000734A1 (es) Compuestos derivados de 4-aminociclohexano sustituido; composicion farmaceutica que comprende a dichos compuestos; y su uso como moduladores del receptor de opioides u y el receptor orl-1 en el tratamiento de la ansiedad, estres, depresion, epilepsia y alzheimer.
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
AR077252A1 (es) Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
AR053344A1 (es) Antagonistas del cgrp,procedimiento para su preparacion,composiciones farmaceuticas que los contienen y usos para el tratamiento de la migrana y otras enfermedades
UY29735A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos
CR8258A (es) Derivados de azepine como agentes farmaceuticos
ECSP055935A (es) Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension
CL2012000925A1 (es) Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras.
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
EA200701705A1 (ru) Антагонисты рецепторы глюкагона, получение и терапевтическое применение
PA8845601A1 (es) Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1)
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
UY28852A1 (es) Nuevos compuestos con estructura de alquino con acción antagonista de mch y medicamentos que contienen estos compuestos
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
EA200700027A1 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
AR050914A1 (es) Agonista receptor de vasopresina peptidico
CL2007003289A1 (es) Compuestos derivados de biciclocarboxiamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades provocadas por la hiperactivacion del receptor vc1 como dolor, enfermedad de vejiga, inflam
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2

Legal Events

Date Code Title Description
FB Suspension of granting procedure